Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxaliplatin
Drug ID BADD_D01633
Description Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin®.
Indications and Usage Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.
Marketing Status approved; investigational
ATC Code L01XA03
DrugBank ID DB00526
KEGG ID D01790
MeSH ID D000077150
PubChem ID 9887053
TTD Drug ID D0Y3ME
NDC Product Code 0703-3986; 13808-502; 0955-1733; 25021-233; 68083-171; 72603-101; 0955-1727; 57884-0017; 63592-0700; 50742-406; 55150-332; 67184-0501; 68083-170; 68083-176; 0955-1731; 72659-865; 43066-014; 68001-468; 71288-101; 82920-704; 16729-332; 45963-611; 67184-0502; 67184-0509; 0781-3317; 0781-9317; 67457-469; 0703-3985; 54875-0006; 67184-0510; 67457-442; 68083-314; 72266-126; 0781-3315; 50742-405; 71288-149; 72266-162; 0781-9315; 55150-331; 61703-363; 63323-750; 67184-0508; 72266-125; 72266-161; 72603-301; 79672-825; 0955-1725; 53104-7649; 67184-0007; 68554-0083; 60505-6132; 68083-177; 79672-826; 14778-0404; 49812-0075; 43066-018
UNII 04ZR38536J
Synonyms Oxaliplatin | Oxalato-(1,2-cyclohexanediamine)platinum II | Oxaliplatin, (SP-4-2-(1R-trans))-isomer | L-OHP Cpd | Platinum(II)-1,2-cyclohexanediamine Oxalate | 1,2-Diaminocyclohexane Platinum Oxalate | 1,2 Diaminocyclohexane Platinum Oxalate | 1,2-Diamminocyclohexane(trans-1)oxolatoplatinum(II) | Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1) | Oxaliplatine | Eloxatine | Eloxatin | Oxaliplatin, (SP-4-3-(cis))-isomer | ACT 078 | ACT-078 | ACT078 | Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II) | Oxaliplatin, (SP-4-2-(1S-trans))-isomer
Chemical Information
Molecular Formula C8H14N2O4Pt
CAS Registry Number 61825-94-3
SMILES C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cytokine release syndrome10.02.01.0100.003806%
Haemodynamic instability24.03.02.0060.000224%Not Available
Gastrointestinal hypomotility07.02.02.0050.000112%Not Available
Lymphatic disorder01.09.01.003--Not Available
Colorectal cancer metastatic16.13.01.005; 07.21.01.0050.000168%Not Available
Foetor hepaticus09.01.05.006; 07.01.06.026--Not Available
Oral pruritus07.05.05.0020.000336%Not Available
Epigastric discomfort07.01.02.0040.000224%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Febrile bone marrow aplasia08.05.02.005; 01.03.03.0070.000112%Not Available
Infusion site pain12.07.05.002; 08.02.05.0140.000280%Not Available
Type III immune complex mediated reaction10.01.03.0230.000336%Not Available
Evans syndrome10.04.01.003; 01.06.01.0020.000336%Not Available
Infusion site oedema12.07.05.013; 08.02.05.0120.000168%Not Available
Tumour necrosis24.04.02.013; 16.32.03.0090.000224%Not Available
Transaminases increased13.03.04.036--Not Available
Cerebral disorder17.02.10.0170.000112%Not Available
Infusion site reaction12.07.05.006; 08.02.05.0050.000414%Not Available
Haemorrhage24.07.01.002--Not Available
Varices oesophageal24.10.02.004; 09.01.06.009; 07.15.05.0010.000951%Not Available
Intra-abdominal haematoma07.12.02.005; 24.07.02.0340.000168%Not Available
Peripheral sensorimotor neuropathy17.09.03.0090.000112%Not Available
Palpable purpura24.12.04.018; 23.06.02.006; 10.02.02.0190.000168%Not Available
Pneumatosis intestinalis07.11.01.0430.000336%Not Available
Temperature intolerance08.01.09.0220.000806%Not Available
Rectal tenesmus15.05.03.011; 07.03.03.001--Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.001701%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.003806%Not Available
Toxic skin eruption23.03.05.003; 10.01.01.008; 12.03.01.0730.000224%Not Available
Metabolic disorder14.11.01.001--Not Available
The 18th Page    First    Pre   18 19 20 21 22    Next   Last    Total 24 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene